We are live on ! Find out more
ELDN icon

Eledon Pharmaceuticals
ELDN

34 hedge funds and large institutions have $89M invested in Eledon Pharmaceuticals in 2021 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

217% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 6

67% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 3

62% more funds holding

Funds holding: 21 → 34 (+13)

1% more capital invested

Capital invested by funds: $88.4M → $89M (+$589K)

342.46% less ownership

Funds ownership: 400.59% → 58.13% (-342%)

Holders
34
Holders Change
+13
Holders Change %
+61.9%
% of All Funds
0.6%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
19
Increased
5
Reduced
3
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
EC
EcoR1 Capital
California
+$16.8M
2
BI
BVF Inc
California
+$5.28M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$5.21M
4
IC
Ikarian Capital
Texas
+$3.77M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$3.41M

Top Sellers

Rank Fund Capital Flow
1
SCM
Stonepine Capital Management
Oregon
-$2.58M
2
MS
Maven Securities
Jersey
-$1.72M
3
ACM
Asymmetry Capital Management
California
-$1.23M
4
O
OrbiMed
New York
-$1.1M
5
Morgan Stanley
Morgan Stanley
New York
-$495K
Name Holding Trade Value Shares
Change 		Change in
Stake
CAM
1
Cormorant Asset Management
Massachusetts
$15.1M – – –
Fidelity Investments
2
Fidelity Investments
Massachusetts
$14.4M +$5.21M +345,100 +34%
EC
3
EcoR1 Capital
California
$11.9M +$16.8M +1,115,721 New
BI
4
BVF Inc
California
$11.9M +$5.28M +350,156 +46%
Adage Capital Partners
5
Adage Capital Partners
Massachusetts
$9.55M – – –
WP
6
Woodline Partners
California
$9.53M -$22.6K -1,500 -0.2%
IC
7
Ikarian Capital
Texas
$2.68M +$3.77M +250,000 New
Vanguard Group
8
Vanguard Group
Pennsylvania
$2.46M +$3.41M +226,001 +5,590%
LGM
9
Logos Global Management
California
$2.4M – – –
Janus Henderson Group
10
Janus Henderson Group
United Kingdom
$2.25M +$3.23M +213,899 New
Point72 Asset Management
11
Point72 Asset Management
Connecticut
$1.34M +$1.89M +125,000 New
Geode Capital Management
12
Geode Capital Management
Massachusetts
$1.06M +$1.5M +99,123 New
CM
13
CM Management
Florida
$803K +$1.13M +75,000 New
ISL
14
Ingalls & Snyder LLC
New York
$547K +$772K +51,149 New
Two Sigma Investments
15
Two Sigma Investments
New York
$402K +$567K +37,569 New
Ensign Peak Advisors
16
Ensign Peak Advisors
Utah
$386K – – –
BFM
17
Boothbay Fund Management
New York
$307K +$433K +28,692 New
Renaissance Technologies
18
Renaissance Technologies
New York
$289K -$244K -16,200 -37%
Citadel Advisors
19
Citadel Advisors
Florida
$268K +$378K +25,062 New
Susquehanna International Group
20
Susquehanna International Group
Pennsylvania
$238K +$336K +22,247 New
Two Sigma Advisers
21
Two Sigma Advisers
New York
$194K +$273K +18,100 New
ECM
22
ExodusPoint Capital Management
New York
$190K +$268K +17,773 New
Northern Trust
23
Northern Trust
Illinois
$166K +$234K +15,528 New
Millennium Management
24
Millennium Management
New York
$156K +$220K +14,588 New
BlackRock
25
BlackRock
New York
$131K +$23.7K +1,568 +15%
1
2

ELDN Hedge Fund Activity: Q1 2021 in Review

34 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in Eledon Pharmaceuticals (ELDN) for Q1 2021, worth a combined $89M — up 0.67% from $88.4M a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new ELDN positions and 6 closed out — a net gain of 13 holders — while 5 added to existing stakes and 3 trimmed.

The largest buyer was EcoR1 Capital, opening a new position worth an estimated $16.8M. The largest seller was Stonepine Capital Management, exiting entirely with an estimated $2.58M sold.

  • 34 institutional investors held Eledon Pharmaceuticals (ELDN) as of Q1 2021, up from 21 in Q4 2020.
  • Funds reported $89M of Eledon Pharmaceuticals stock for Q1 2021, up 0.67% quarter-over-quarter.
  • 19 funds opened new Eledon Pharmaceuticals positions in Q1 2021 and 6 closed out, a net change of +13 holders.
  • The largest Eledon Pharmaceuticals buyer in Q1 2021 was EcoR1 Capital, an estimated $16.8M added.
  • The largest Eledon Pharmaceuticals seller in Q1 2021 was Stonepine Capital Management, an estimated $2.58M sold.

Based on aggregated 13F filings for Q1 2021.